UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/709,880	06/03/2004	David M. Richlin	RICHP001US	9853
27949 7590 01/09/2008 LAW OFFICE OF JAY R. YABLON			EXAMINER	
,	MBERLAND DRIVE		KENNEDY, SHARON E	
SCHENECTAL	DY, NY 12309-2814		ART UNIT PAPER NUMBER	
·		•	1615	
			MAIL DATE	DELIVERY MODE
			<u> </u>	
•			01/09/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(a)	
Office Action Summary		Application No.	Applicant(s)	
		10/709,880	RICHLIN ET AL.	
Office P	cuon Summary	Examiner	Art Unit	
		Sharon E. Kennedy	1615	
The MAILIN Period for Reply	G DATE of this communication app	pears on the cover sheet with the o	correspondence address	
WHICHEVER IS LO - Extensions of time may after SIX (6) MONTHS if If NO period for reply is - Failure to reply within th Any reply received by th	TATUTORY PERIOD FOR REPL' ONGER, FROM THE MAILING Do be available under the provisions of 37 CFR 1.1 rom the mailing date of this communication. specified above, the maximum statutory period to e set or extended period for reply will, by statute e Office later than three months after the mailing stment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tir will apply and will expire SIX (6) MONTHS from a. cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. \$ 133)	
Status				
2a) ☐ This action is 3) ☐ Since this ap	to communication(s) filed on FINAL. 2b) This plication is in condition for alloware ordance with the practice under E	action is non-final. nce except for formal matters, pro		
Disposition of Claims			·	
4a) Of the above the first term of the above te	50 is/are pending in the application ove claim(s) is/are withdraw 150 is/are allowed. 13-16 and 22 is/are rejected. 2,17-21 and 23-65 is/are objected are subject to restriction and/out the solution is objected to by the Examine solution is objected to the drawing sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration is objected to by the Examine sheet(s) including the correct eclaration sheet(s) in the sheet eclaration sheet eclaration sheet eclaration sheet	wn from consideration. to. r election requirement. r. p⊠ accepted or b) □ objected to drawing(s) be held in abeyance. Section is required if the drawing(s) is objected in the drawing(s) is objected to drawing(s) is objected to drawing(s) is objected to drawing(s) is objected in the drawing(s) is object	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.				
Attachment(s) X Notice of References (continue) Notice of Draftsperson X Information Disclosure Paper No(s)/Mail Date	's Patent Drawing Review (PTO-948) Statement(s) (PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite	

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-8, 13-16, 22 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Rubin, US 5,059,603. Broadly interpreted, the claims are anticipated by the Rubin disclosure. Applicant claims a preparation for topical application comprising a vasoconstrictor and a penetration enhancer. Applicant states in the claims that the vasoconstrictor is for retarding vascular dispersion of a therapeutic agent. The Rubin vasoconstrictor functions to treat impotence. Although Rubin does not disclose that the vasoconstrictor inhibits vascular dispersion, this function inherently occurs. Accordingly, the claims are anticipated. Regarding claims directed to the composition percentages, see Example 2 in column 9 and column 4, second paragraph.

Allowable Subject Matter

Claims 9-12, 17-21, 23-65 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 66-150 are allowed.

The following is a statement of reasons for the indication of allowable subject matter: The claims recite embodiments which would not be envisioned when reviewing the Rubin disclosure. For example, the anesthetics are not likely to be included. Claim 66 is allowed in contrast to claim 1. The vasoconstrictor of Rubin is not functioning as a method to control agent dispersion.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharon E. Kennedy whose telephone number is 571/272-4948. The examiner can normally be reached on Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on 571/272-8373.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Sharon E. Kennedy/ Sharon E. Kennedy Primary Examiner Art Unit 1615